Redundant immune pathways explain the high efficacy of mRNA-LNP vaccines

mRNA-LNP vaccines bypass the traditional biological gatekeepers required for T cell activation, a feat previously thought impossible due to the rigid specialisation of dendritic cells. While most vaccines rely on a single pathway—cDC1-mediated cross-presentation—these lipid-wrapped instructions engage multiple cellular routes simultaneously. This ensures that the immune system remains alert even if one specific cell type is suppressed by disease. Investigation into the murine immune response reveals that mRNA-LNP vaccines function independently of the WDFY4-dependent pathway. Instead, they recruit both cDC1 and cDC2 cells to prime CD8+ T cells, a redundancy not typically seen in protein-based counterparts. This suggests that the lipid nanoparticle delivery system does more than just protect the genetic code; it actively alters how the immune system organises its response.

The mechanics of mRNA-LNP vaccines

Researchers identified 'cross-dressing' as a primary driver of this efficacy. In this process, dendritic cells strip peptide-MHC complexes from non-haematopoietic cells that have already translated the mRNA. This direct acquisition of immune signals allows for rapid T cell mobilisation and memory formation. Unlike older methods that require internal processing of antigens, this method relies on ready-made complexes.

• Redundancy ensures immune activation even if one cellular pathway is compromised.
• Cross-dressing explains why these vaccines might trigger responses against non-encoded antigens.
• Type I interferon remains the essential catalyst for this cellular hand-off.

This flexibility suggests that mRNA platforms are uniquely suited for complex environments, such as immunosuppressive tumours. However, the study does not solve whether this broad cellular engagement increases the risk of off-target immune reactions in sensitive tissues.